Artes founder resigns:
This article was originally published in Clinica
Dr Stefan Lemperle, the founder of Artes Medical, the San Diego, California-based developer of aesthetic injectable products, has handed the reins over to the company's president and chief operating officer Diane Goostree. Ms Goostree takes on her new roles as CEO and president with immediate effect. Dr Lemperle, who is planning to focus on developing new medical technologies for "underserved markets", is stepping down after helping the company achieve FDA approval for its ArteFill dermal filler in October. The product is said to be the first FDA-approved non-resorbable aesthetic injectable implant and its US launch has been slated for the first quarter of 2007. The company will compete head to head with other dermal fillers such as Botox (botulinum toxin type A).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.